UK Markets closed

Clinigen Group plc (CLIGF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
8.650.00 (0.00%)
At close: 11:18AM EDT

Clinigen Group plc

Pitcairn House
Crown Square Centrum 100
Burton-on-Trent DE14 2WW
United Kingdom
44 1283 495 010

Full-time employees1,250

Key executives

NameTitlePayExercisedYear born
Mr. Shaun Edward ChiltonCEO & Exec. Director1.55MN/A1968
Mr. Nicholas P. KeherCFO & Exec. Director774.15kN/AN/A
Mr. Sam HerbertChief Operating OfficerN/AN/AN/A
Matt ParrishHead of Investor RelationsN/AN/AN/A
Ms. Amanda MillerGen. Counsel & Company Sec.N/AN/AN/A
Mr. David BryantDirector of Corp. Devel.N/AN/AN/A
Jessica ArcherGlobal HR DirectorN/AN/AN/A
Mr. Mark CorbettManaging Director of Global Access DivisionN/AN/AN/A
Mr. Johannes WillemseChief Commercial OfficerN/AN/A1968
Mr. Ivo Timmermans M.D., MBAChief Medial OfficerN/AN/A1960
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through three segments: Commercial Medicines, Unlicensed Medicines, and Clinical Services. The Commercial Medicines segment acquires and licenses commercial medicines and then revitalises them, as well as provides access to licensed and branded generic medicines. The Unlicensed Medicines segment is involved in sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet medical need. The Clinical Services segment packages, supplies, distributes, and manages comparator medicines and services to clinical trials and investigator initiated trials. It offers Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Proleukin for the treatment of kidney cancer; Imukin that is used in chronic granulomatous disease; Totect, a dexrazoxane product; Foscavir, an anti-virals which work by stopping viruses from multiplying in number; AZEDR for the treatment of adult and pediatric patients; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom.

Corporate governance

Clinigen Group plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.